Mol Oncol 2010,
Prager, Gerald W; Lackner, Eva-Maria; Krauth, Maria-Theresa; Unseld, Matthias; Poettler, Marina; Laffer, Sylvia; Cerny-Reiterer, Sabine; Lamm, Wolfgang; Kornek, Gabriela V; Binder, Bernd R; Zielinski, Christoph C; Valent, Peter
Cancer progression is often associated with the formation of malignant effusions. Vascular endothelial growth factor (VEGF) is a major regulator of vascular permeability and has been implicated as mediator of tumor progression. We examined the production and secretion of VEGF(165) in various primary cancer cells derived from malignant effusions, and the role of exogenous VEGF(165) as a mediator of effusion formation. VEGF(165) was constantly secreted by all cultured tumor cells in an mTOR-dependent manner, as it was inhibited by the mTOR inhibitor rapamycin. Secreted VEGF(165) showed functional activity by inducing endothelial leakiness and tumor cell-transendothelial migration in vitro, effects which could be reverted by the anti-VEGF antibody bevacizumab. Thus, mTOR inhibitors as well as bevacizumab should be considered as potential agents in cancer patients suffering from malignant effusions.
Diseases/Pathways annotated by Medline MESH:
Document information provided by NCBI PubMed
Text Mining Data
VEGF — mTOR: " VEGF
( 165 ) was constantly secreted by all cultured tumor cells in an mTOR
dependent manner, as it was inhibited by the mTOR inhibitor rapamycin "
Manually curated Databases
No curated data.